A top-20 pharma company told Medrio CEO Mike Novotny it spends $100 million a year just integrating one of its enterprise systems, and that figure doesn’t include the software licenses themselves. Small and midsize sponsors can’t absorb a cost like that, which is exactly why fragmented eClinical technology has sat at the top of their complaint list for three decades without anyone solving it.

Novotny founded Medrio 21 years ago, stepped away as CEO after 15 years, spent five years away, and returned a year ago because, by his account, the integration problem is now actually fixable. The company launched a new Medrio CTMS this month as part of a connected platform where data created in EDC is automatically available in the eTMF, and a site monitor pulling up visit details can see EDC monitoring progress in the same interface. No middleware, no manual reconciliation. The design targets the scenario Novotny describes as the core pain point: a sponsor running Medrio’s ePRO alongside a different vendor’s RTSM, a third vendor’s EDC, and a fourth vendor’s CTMS, then stitching everything together with spreadsheets.

The scale of that stitching cost is not unique to the pharma giants. Integration work typically adds 15 to 30 percent on top of base software subscription costs, according to Gartner analysts, and that’s before accounting for the validation burden each connection point creates under FDA guidance on electronic records in clinical investigations,. For a 20-person sponsor running two or three concurrent trials, the overhead isn’t just expensive; it draws headcount away from the science. PharPoint is among the early adopters already shaping the CTMS rollout, with the program open to additional companies who want to influence the product direction before general release.

The practical test for Medrio’s thesis will come once a meaningful cohort of sponsors has run a full study on the connected platform and can compare their data-reconciliation hours against prior trials. That number, not the launch announcement, is what determines whether the problem Novotny spent 30 years hearing about is actually behind them.

Source link: https://medrio.com/blog/fragmented-clinical-trial-technology-mike-novotny/

Website | + posts

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.